Evolent Health, Inc (NYSE:EVH) Receives Consensus Rating of “Moderate Buy” from Analysts

Evolent Health, Inc (NYSE:EVH) has received a consensus rating of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $5.9643.

EVH has been the subject of a number of recent research reports. Citigroup upgraded shares of Evolent Health from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $6.75 to $6.00 in a research note on Monday, August 10th. JPMorgan Chase & Co. increased their target price on Evolent Health from $5.00 to $6.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 18th. TD Cowen increased their target price on Evolent Health from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Canaccord Genuity Group cut their price target on Evolent Health from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, August 10th. Finally, Needham & Company LLC lifted their price target on Evolent Health from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, May 7th.

Evolent Health Price Performance

NYSE EVH opened at $4.73 on Tuesday. The company has a quick ratio of 1.24, a current ratio of 1.24 and a debt-to-equity ratio of 2.52. The company has a market cap of $534.77 million, a PE ratio of -1.04 and a beta of 0.79. Evolent Health has a 52 week low of $2.10 and a 52 week high of $10.08. The firm’s 50-day simple moving average is $4.77 and its two-hundred day simple moving average is $3.78.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, August 6th. The technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The firm had revenue of $484.50 million during the quarter, compared to the consensus estimate of $597.70 million. During the same quarter last year, the company earned ($0.10) earnings per share. The company’s revenue was up 46.9% on a year-over-year basis. Research analysts predict that Evolent Health will post -0.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in EVH. Durable Capital Partners LP bought a new stake in shares of Evolent Health during the second quarter valued at about $72,326,000. Rubicon Founders LLC purchased a new stake in shares of Evolent Health in the third quarter worth about $49,204,000. 8 Knots Management LLC bought a new position in shares of Evolent Health in the second quarter valued at approximately $32,802,000. Goldman Sachs Group Inc. boosted its position in shares of Evolent Health by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after acquiring an additional 1,754,520 shares during the period. Finally, Maverick Capital Ltd. boosted its position in shares of Evolent Health by 1.3% in the first quarter. Maverick Capital Ltd. now owns 2,572,763 shares of the technology company’s stock valued at $5,866,000 after acquiring an additional 32,833 shares during the period.

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.